The London Life Sciences team advised Quanta on its over $60 million Series E funding round led by Novo Holdings, Glenview Capital and b2venture, with participation from existing investors.
Quanta Dialysis Technologies is committed to making dialysis accessible to every patient, in every setting, with its Quanta Dialysis System, which provides the clinical versatility needed to deliver kidney replacement therapy across multiple care settings. The device is designed to be operated by a broad range of users to bring dialysis directly to patients. The company intends to use the additional funds to expand its commercial presence in the US and continue to invest in innovation within the sector.
The Goodwin deal team included Sophie McGrath, Richard Bloomfield, Matthew Lee, Sonja Jounus and Priscilla Alao.
For more details on the financing, please see here.